الفهرس | Only 14 pages are availabe for public view |
Abstract Hepatitis C virus (HCV) infection is a major global health issue. The standard of care (SOC) therapy for HCV was combination of pegylated interferon (PEG/IFN) and ribavirin (RBV). Almost all patients treated with PEG/IFN and RBV experience one or more adverse events during the course of therapy. Among these adverse effects is its affection on hearing and vestibular system. |